The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present disclosure relates to a composition for preventing, relieving or treating climacteric symptoms, the composition comprising lactic acid bacteria and prebiotic composition. The lactic acid bacteria of the present disclosure have β-glucosidase activity and a very excellent ability to convert isoflavones into equol compounds, and thus may exhibit estrogenic activity through synergism with the gut microbiota. Therefore, the lactic acid bacteria of the present disclosure may be effectively used for the prevention, relief or treatment of women's climacteric or menopausal symptoms.

The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.

The present invention relates to compositions and methods for producing fermented milk products with increased amount of probiotic bacteria. In particular, the invention relates to a process for producing a fermented milk which comprises adding to a milk base (i) a starter culture comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactobacillus strain, which is capable of metabolizing a non-lactose carbohydrate, (ii) one or more non-lactose carbohydrate capable of being metabolized by the lactic acid bacteria, in an amount measured so as to become depleted when the pH of the fermented milk product is between 4.9 and 5.5 and (iii) a probiotic strain selected from a Lactobacillus strain and a Bifidobacterium strain. In addition, the present invention relates to compositions and to fermented milk food or feed products produced by the process of the invention.

The combination of specific immunoglobulins plus activated Bifidobacteria strains or other beneficial bacteria is described with the designed efficacy to colonize unstable microbiome communities in humans or other animals, restoring the keystone Bifidobacteria strains or other beneficial bacteria to compositional and functional importance in the intestine and improve overall health and reduce pathogenic infections in the host. Secretory immunoglobulin A (SIgA), when bound via specific glycans to select commensal bacteria grown on human milk oligosaccharides (HMOs), enhances the colonization potential of commensals through protection from intestinal digestion, enhancing attachment, and dampening host immune response.

The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

An object of the present invention is to provide a technique for further promoting growth of bacteria belonging to the genus Bifidobacterium. By combining lactoferrin and/or lactoferrin hydrolyzate, and human milk oligosaccharides, a synergistic growth promoting effect of the bacteria belonging to the genus Bifidobacterium is achieved. Preferably, the human milk oligosaccharides include one or more selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, and lactodifucotetraose. In addition, preferably, the bacteria belonging to the genus Bifidobacterium include one or more selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum.

An object of the present invention is to provide a technique for further promoting growth of bacteria belonging to the genus Bifidobacterium. By combining lactoferrin and/or lactoferrin hydrolyzate, and human milk oligosaccharides, a synergistic growth promoting effect of the bacteria belonging to the genus Bifidobacterium is achieved. Preferably, the human milk oligosaccharides include one or more selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, and lactodifucotetraose. In addition, preferably, the bacteria belonging to the genus Bifidobacterium include one or more selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum.

This disclosure describes compositions of one or more components including milk fat globule membranes (MFGM) complexes, milk fat globules (MFG), commensal organisms, SlgA, recombinant SlgA (rSlgA), triglycerides or oils, and mammalian milk oligosaccharides (MMO) and the use of such compositions. The reconstituted MFGM component of the disclosed invention may come from an animal source, particularly from a mammalian source, including from the processing of buttermilk.

This disclosure describes compositions of one or more components including milk fat globule membranes (MFGM) complexes, milk fat globules (MFG), commensal organisms, SlgA, recombinant SlgA (rSlgA), triglycerides or oils, and mammalian milk oligosaccharides (MMO) and the use of such compositions. The reconstituted MFGM component of the disclosed invention may come from an animal source, particularly from a mammalian source, including from the processing of buttermilk.